Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary
  1. Rosalind M. Glasspool, MBBS, PhD, FRCP*,
  2. Antonio González Martín, MD,
  3. David Millan, BSc, MB ChB, FRCPath,
  4. Domenica Lorusso, MD§,
  5. Elisabeth Åvall-Lundqvist, MD, PhD,
  6. Jean A. Hurteau, MD,
  7. Alison Davis, MBBS, MSc, FRACP#,
  8. Felix Hilpert, MD, PhD**,
  9. Jae-Weon Kim, MD, PhD,,
  10. Jérôme Alexandre, MD, PhD, and
  11. Jonathan A. Ledermann, MD, FRCP§§
  1. *Beatson West of Scotland Cancer Centre, Glasgow, UK (SGCTG);
  2. Medical Oncology Department, MD Anderson Cancer Centre, Madrid, Spain (GEICO);
  3. Southern General Hospital, Glasgow, UK (SGCTG);
  4. §Gynecologic Oncology Unit, Fondazione IRCCS National Cancer institute of Milan (MITO), Milan, Italy;
  5. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (NSGO);
  6. Division of Gynecologic Oncology, NorthShore University Health System, University of Chicago Pritzker School of Medicine, Evanston, IL (GOG);
  7. #The Canberra Hospital, Canberra, Australia (ANZGOG);
  8. **University Hospital of Schleswig-Holstein Campus, Kiel, Germany (AGO);
  9. ††Department of Obstectrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea (KGOG);
  10. ‡‡Medical Oncology, Cochin-Hôtel Dieu, Paris Descartes University, Paris, France (GINECO); and
  11. §§UCL Cancer Institute, London, UK (NCRI/MRC).
  1. Address correspondence and reprint requests to Rosalind M. Glasspool, MBBS, PhD, FRCP, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, United Kingdom. E-mail: ros.glasspool{at}


Abstract Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.

  • Squamous cell carcinoma of ovary
  • Mature teratoma
  • Mature cystic teratoma
  • GCIG
  • Review

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.